Morbidity and mortality among patients with respiratory syncytial virus infection: a 2-year retrospective review

Neil W. Anderson, Matthew J. Binnicker, Dana M. Harris, Razvan M. Chirila, Lisa Brumble, Jayawant Mandrekar, D. Jane Hata

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Previous studies have demonstrated high morbidity and mortality for adult patients with respiratory syncytial virus (RSV) infection. We performed a retrospective, multicenter, two-year chart review of all patients (n = 334) testing positive for RSV by the ProFlu + ® Influenza A/B and RSV assay (Hologic, Bedford, MA). We analyzed indicators of morbidity and mortality in children <6 years old, immunocompetent and immunosuppressed adults, and transplant patients. Significant morbidity and mortality was observed among hematopoietic stem cell transplant patients (7.3%, 60-day mortality), solid organ transplant patients (13.3%, 60-day mortality), and COPD patients (12.8%, 60-day mortality). Of the patients positive for RSV, 144 (43.1%) of 334 received antibacterials or antifungals following diagnosis. Of these patients, a bacterial or fungal pathogen was not recovered from 60% of cases. Despite advances in RSV treatment, certain populations appear to be inadequately treated, while others appear to be inappropriately treated with unnecessary antimicrobials.

Original languageEnglish (US)
Pages (from-to)367-371
Number of pages5
JournalDiagnostic Microbiology and Infectious Disease
Volume85
Issue number3
DOIs
StatePublished - Jul 1 2016

Fingerprint

Respiratory Syncytial Virus Infections
Morbidity
Respiratory Syncytial Viruses
Mortality
Transplants
Child Mortality
Hematopoietic Stem Cells
Chronic Obstructive Pulmonary Disease
Human Influenza

Keywords

  • Chronic obstructive pulmonary disease
  • RSV
  • Transplant

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Morbidity and mortality among patients with respiratory syncytial virus infection : a 2-year retrospective review. / Anderson, Neil W.; Binnicker, Matthew J.; Harris, Dana M.; Chirila, Razvan M.; Brumble, Lisa; Mandrekar, Jayawant; Hata, D. Jane.

In: Diagnostic Microbiology and Infectious Disease, Vol. 85, No. 3, 01.07.2016, p. 367-371.

Research output: Contribution to journalArticle

Anderson, Neil W. ; Binnicker, Matthew J. ; Harris, Dana M. ; Chirila, Razvan M. ; Brumble, Lisa ; Mandrekar, Jayawant ; Hata, D. Jane. / Morbidity and mortality among patients with respiratory syncytial virus infection : a 2-year retrospective review. In: Diagnostic Microbiology and Infectious Disease. 2016 ; Vol. 85, No. 3. pp. 367-371.
@article{20feb2f0e25d45c590b3b64210d61b0a,
title = "Morbidity and mortality among patients with respiratory syncytial virus infection: a 2-year retrospective review",
abstract = "Previous studies have demonstrated high morbidity and mortality for adult patients with respiratory syncytial virus (RSV) infection. We performed a retrospective, multicenter, two-year chart review of all patients (n = 334) testing positive for RSV by the ProFlu + {\^A}{\circledR} Influenza A/B and RSV assay (Hologic, Bedford, MA). We analyzed indicators of morbidity and mortality in children <6 years old, immunocompetent and immunosuppressed adults, and transplant patients. Significant morbidity and mortality was observed among hematopoietic stem cell transplant patients (7.3{\%}, 60-day mortality), solid organ transplant patients (13.3{\%}, 60-day mortality), and COPD patients (12.8{\%}, 60-day mortality). Of the patients positive for RSV, 144 (43.1{\%}) of 334 received antibacterials or antifungals following diagnosis. Of these patients, a bacterial or fungal pathogen was not recovered from 60{\%} of cases. Despite advances in RSV treatment, certain populations appear to be inadequately treated, while others appear to be inappropriately treated with unnecessary antimicrobials.",
keywords = "Chronic obstructive pulmonary disease, RSV, Transplant",
author = "Anderson, {Neil W.} and Binnicker, {Matthew J.} and Harris, {Dana M.} and Chirila, {Razvan M.} and Lisa Brumble and Jayawant Mandrekar and Hata, {D. Jane}",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.diagmicrobio.2016.02.025",
language = "English (US)",
volume = "85",
pages = "367--371",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Morbidity and mortality among patients with respiratory syncytial virus infection

T2 - a 2-year retrospective review

AU - Anderson, Neil W.

AU - Binnicker, Matthew J.

AU - Harris, Dana M.

AU - Chirila, Razvan M.

AU - Brumble, Lisa

AU - Mandrekar, Jayawant

AU - Hata, D. Jane

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Previous studies have demonstrated high morbidity and mortality for adult patients with respiratory syncytial virus (RSV) infection. We performed a retrospective, multicenter, two-year chart review of all patients (n = 334) testing positive for RSV by the ProFlu + ® Influenza A/B and RSV assay (Hologic, Bedford, MA). We analyzed indicators of morbidity and mortality in children <6 years old, immunocompetent and immunosuppressed adults, and transplant patients. Significant morbidity and mortality was observed among hematopoietic stem cell transplant patients (7.3%, 60-day mortality), solid organ transplant patients (13.3%, 60-day mortality), and COPD patients (12.8%, 60-day mortality). Of the patients positive for RSV, 144 (43.1%) of 334 received antibacterials or antifungals following diagnosis. Of these patients, a bacterial or fungal pathogen was not recovered from 60% of cases. Despite advances in RSV treatment, certain populations appear to be inadequately treated, while others appear to be inappropriately treated with unnecessary antimicrobials.

AB - Previous studies have demonstrated high morbidity and mortality for adult patients with respiratory syncytial virus (RSV) infection. We performed a retrospective, multicenter, two-year chart review of all patients (n = 334) testing positive for RSV by the ProFlu + ® Influenza A/B and RSV assay (Hologic, Bedford, MA). We analyzed indicators of morbidity and mortality in children <6 years old, immunocompetent and immunosuppressed adults, and transplant patients. Significant morbidity and mortality was observed among hematopoietic stem cell transplant patients (7.3%, 60-day mortality), solid organ transplant patients (13.3%, 60-day mortality), and COPD patients (12.8%, 60-day mortality). Of the patients positive for RSV, 144 (43.1%) of 334 received antibacterials or antifungals following diagnosis. Of these patients, a bacterial or fungal pathogen was not recovered from 60% of cases. Despite advances in RSV treatment, certain populations appear to be inadequately treated, while others appear to be inappropriately treated with unnecessary antimicrobials.

KW - Chronic obstructive pulmonary disease

KW - RSV

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=84970023412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970023412&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2016.02.025

DO - 10.1016/j.diagmicrobio.2016.02.025

M3 - Article

C2 - 27179369

AN - SCOPUS:84970023412

VL - 85

SP - 367

EP - 371

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 3

ER -